Cargando…

Efficacy and safety of the use of omalizumab in a patient with difficult-to-control severe asthma and antiphospholipid antibody syndrome

Detalles Bibliográficos
Autores principales:	Villela, Rosangela, Melo, Janaina M, Nociti, Thais, Araujo, Ana Carla S, Arruda, L Karla
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	World Allergy Organization 2015
Materias:	Meeting Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4407072/ http://dx.doi.org/10.1186/1939-4551-8-S1-A219

Ejemplares similares

Characterization of aspirin-sensitivity in patients with asthma and chronic rhinosinusitis without a history of symptoms upon acetyl-salicylic acid (ASA) ingestion: a case series
por: Souza, Phelipe, et al.
Publicado: (2015)

Hydroa vacciniforme as a differential diagnosis of atopic dermatitis
por: Brom, Lucas, et al.
Publicado: (2015)

Diagnostic profile among patients with chronicurticaria/angioedema attending a reference clinic in Brazil: the role of auto-immunity
por: Cordeiro, Daniel, et al.
Publicado: (2015)

Hypertrophic lichen planus-like atopic dermatitis: a case report
por: De Castro, Maria Eduarda Pontes Cunha, et al.
Publicado: (2015)

Omalizumab is effective in the treatment of difficult-to-treat chronic spontaneous urticaria
por: Forgie, Jennifer, et al.
Publicado: (2014)

Omalizumab: clinical use for the treatment of an adolescent with difficult asthma
por: De Castro, Giovanna, et al.
Publicado: (2013)

Health outcomes, education, healthcare delivery and quality – 3051. Profiles of diagnosis and treatment of asthma in the public health system in Brazil
por: Melo, Janaina M, et al.
Publicado: (2013)

Omalizumab treatment of moderate to severe asthma in the adolescent and pediatric population
por: O’Quinn, John, et al.
Publicado: (2014)

A systematic intervention for assistance of patients with asthma in Brazil: partnership between university and public health system
por: Palhas, Priscila, et al.
Publicado: (2015)

A case report of ABPA, cystic fibrosis and asthma treated with omalizumab
por: Mazza, JA, et al.
Publicado: (2015)

Xolair® (omalizumab) enrollment in a tertiary care allergy and asthma clinic in Canada
por: Cameron, Jodi, et al.
Publicado: (2014)

Eculizumab in recalcitrant antiphospholipid antibody syndrome
por: Zapantis, Ekaterini, et al.
Publicado: (2014)

4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry
por: Snelder, S. M., et al.
Publicado: (2017)

Efficacy of Omalizumab therapy in a case of severe atopic dermatitis
por: Barrios, Jonathan Lacombe, et al.
Publicado: (2011)

Cerebrovascular insult and antiphospholipid antibodies in young adults
por: Cucnik, S, et al.
Publicado: (2002)

Follow-up of asthma control and quality of life after discontinuation of omalizumab in severe asthmatic patients
por: Nayci, Sibel, et al.
Publicado: (2015)

Poster 1012: Safety and efficacy of omalizumab in 10 children with asthma and other allergic comorbidities
por: Aguiar, Rita, et al.
Publicado: (2014)

The observed incidence of anaphylaxis and serum sickness in patients receiving omalizumab in a tertiary allergy and asthma clinic in Canada
por: MacRae, Megan, et al.
Publicado: (2014)

Prothrombin fragment F1+2 in patients with antiphospholipid antibodies
por: Ambrozic, A, et al.
Publicado: (2004)

Asthma diagnosis and treatment – 1015. Improvements in lung function in an indian population with IgE mediated asthma receiving omalizumab in a real-world setting
por: Guleria, Randeep, et al.
Publicado: (2013)

Severe asthma and the omalizumab option
por: Miller, Christopher WT, et al.
Publicado: (2008)

Omalizumab treatment in brittle asthma
por: Skiepko, Roman, et al.
Publicado: (2014)

Do IgA antiphospholipid antibodies have any clinical importance?
por: Gaspersic, GN, et al.
Publicado: (2002)

Role of the asthma predictive index (API) in assessing the development of asthma among Brazilian children
por: Albuquerque, Luciana, et al.
Publicado: (2015)

Efficacy and safety of omalizumab therapy in urticaria vasculitis
por: Petrelli, Fiorella, et al.
Publicado: (2022)

Omalizumab for Severe Asthma: Beyond Allergic Asthma
por: Loureiro, C. C., et al.
Publicado: (2018)

Real-life effectiveness of omalizumab in difficult-to-treat versus severe asthma: a national cohort study in Belgium
por: Verhamme, Katia M.C., et al.
Publicado: (2019)

Antiphospholipid antibodies and thrombosis in severe COVID-19 pneumonia: A difficult relationship
por: Pavoni, Vittorio, et al.
Publicado: (2020)

Country-based report: the safety of omalizumab treatment in pregnant patients with asthma
por: GEMİCİOĞLU, Bilun, et al.
Publicado: (2021)

Severe pediatric asthma therapy: Omalizumab—A systematic review and meta-analysis of efficacy and safety profile
por: Fenu, Grazia, et al.
Publicado: (2023)

Effects of omalizumab on chronic urticaria not responding to recommended therapy
por: Hébert, Jacques, et al.
Publicado: (2012)

Primary care doctor's diagnosis of difficult-to-treat asthma in school age children
por: Wolthers, Ole D, et al.
Publicado: (2015)

Omalizumab: Clinical Use for the Management of Asthma
por: Thomson, Neil C., et al.
Publicado: (2012)

Omalizumab's efficacy and safety against chronic spontaneous urticaria
por: Özdemir, Öner
Publicado: (2023)

Measured depth of subcutaneous tissue on posterolateral arm of omalizumab patients
por: Potts, Ryan, et al.
Publicado: (2012)

Omalizumab in chronic spontaneous urticaria (CSU): experience in three cases
por: Valle, Solange Oliveira Rodrigues, et al.
Publicado: (2015)

Antibodies to beta(2)-glycoprotein I, prothrombin and antithrombin III as markers of the antiphospholipid syndrome severity
por: Zabek, J, et al.
Publicado: (2001)

Health outcomes, education, healthcare delivery and quality – 3038: The relation of sTRAIL levels and quality of life in omalizumab using severe persistent allergic asthma patients
por: Yalcin, Arzu Didem, et al.
Publicado: (2013)

Oral challenge test with nsaids: evaluation of patients attending a specialty clinic in Ribeirão Preto, Brazil
por: Menezes, Ullissis, et al.
Publicado: (2015)

Update on optimal use of omalizumab in management of asthma
por: Pelaia, Girolamo, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_88ne41m6a6uqsp3iev3fj9cfhc